Abstract
We describe a patient with acute promyelocytic leukemia (APL) and the karyotype 46,XX,i(17)(q10) with PML-RARA fusion gene detected by fluorescence in situ hybridization (FISH) and nested reverse transcriptase-polymerase chain reaction (RT-PCR). FISH using dual-color translocation probes for PML (promyelocytic leukemia) and RARA (retinoic acid receptor-alpha) showed fusion signal for PML-RARA on both arms of i(17q). The patient attained complete remission (CR) with all-trans retinoic acid treatment and became PML-RARA negative. One year later, while PML-RARA negative on FISH and RT-PCR, the patient presented with thrombocytopenia. Bone marrow examination suggested an acute monoblastic leukemia (AML-M5a) including the karyotype 46,XX,t(8;16) (p11.2;p13.3),inv(11)(p15q22 approximately q23)[11]/47,idem,+i(8)(q10)[9]. She is currently in CR. The occurrence of therapy related acute leukemia after successful therapy for APL is an emerging problem.
MeSH terms
-
Antineoplastic Agents / adverse effects*
-
Chromosomes, Human, Pair 17*
-
Female
-
Humans
-
In Situ Hybridization, Fluorescence
-
Isochromosomes*
-
Karyotyping
-
Leukemia, Monocytic, Acute / chemically induced*
-
Leukemia, Promyelocytic, Acute / genetics*
-
Middle Aged
-
Neoplasm Proteins / genetics*
-
Nuclear Proteins / genetics
-
Oncogene Proteins, Fusion / genetics*
-
Promyelocytic Leukemia Protein
-
Receptors, Retinoic Acid / genetics*
-
Retinoic Acid Receptor alpha
-
Reverse Transcriptase Polymerase Chain Reaction
-
Transcription Factors / genetics
-
Translocation, Genetic
-
Tretinoin / adverse effects*
-
Tumor Suppressor Proteins
Substances
-
Antineoplastic Agents
-
Neoplasm Proteins
-
Nuclear Proteins
-
Oncogene Proteins, Fusion
-
Promyelocytic Leukemia Protein
-
RARA protein, human
-
Receptors, Retinoic Acid
-
Retinoic Acid Receptor alpha
-
Transcription Factors
-
Tumor Suppressor Proteins
-
promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
-
PML protein, human
-
Tretinoin